<DOC>
	<DOCNO>NCT01227135</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Biological therapy , hydroxychloroquine , may stimulate immune system different way stop cancer cell grow . It yet know whether imatinib mesylate effective give without hydroxychloroquine treat patient chronic myeloid leukemia . PURPOSE : This randomized phase II trial study side effect give imatinib mesylate without hydroxychloroquine see well work treat patient chronic myeloid leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate With Without Hydroxychloroquine Treating Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine imatinib mesylate versus hydroxychloroquine ( HCQ ) imatinib mesylate effective term BCR/ABL level patient chronic myeloid leukemia major cytogenetic response ( MCyR ) residual BCR/ABL-positive cell detectable quantitative polymerase chain reaction least one year imatinib mesylate treatment . - To determine safety tolerability regimen patient . Secondary - To determine whether introduction HCQ influence imatinib mesylate plasma level . - To determine whole blood HCQ level achieve combination imatinib mesylate expect range . - To determine HCQ inhibits autophagy vivo . - To evaluate effect regimen residual BCR/ABL-positive primitive progenitor . OUTLINE : This multicenter study . Patients stratify accord baseline polymerase chain reaction ( PCR ) level ( &lt; 3 log baseline v ≥ 3 log baseline ) , time imatinib mesylate ( 12 &lt; 24 month vs 24 &lt; 36 month ) , imatinib mesylate dose ( &lt; 400 mg v 400 mg &lt; 600 mg v 600 mg 800 mg ) , center . Patients randomize 1 2 treatment arm . - Arm A : Patients receive oral imatinib mesylate daily . Treatment repeat every 4 week 12 month absence disease progression unacceptable toxicity . - Arm B : Patients receive oral imatinib mesylate daily oral hydroxychloroquine ( HCQ ) twice daily . Treatment repeat every 4 week 12 month absence disease progression unacceptable toxicity . In arm , patient may receive oral imatinib mesylate daily another 12 month follow period study . Consenting patient undergo blood sample bone marrow collection baseline , , completion study therapy pharmacologic laboratory study . After completion study treatment , patient follow 3 , 6 , 9 , 12 month . Peer Reviewed , Funded MRC support Cancer Research UK</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myeloid leukemia ( CML ) chronic phase ( CP ) Has treat imatinib mesylate least 1 year Receiving stable dose ≥ 6 month prior randomization Achieved least major cytogenetic response ( MCyR ) continue BCR/ABLpositive quantitative polymerase chain reaction ( QPCR ) Must fusion gene present monitor QPCR PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ ( stable within normal range ≥ 2 month ) Platelet count ≥ 100,000/mm³ ( stable within normal range ≥ 2 month ) Serum albumin &gt; 3 g/dL AST and/or ALT ≤ 2.5 time upper limit normal ( ULN ) Serum bilirubin ≤ 1.5 time ULN Serum creatinine ≤ 1.5 time ULN OR 24hour creatinine clearance ≥ 50 mL/min Serum potassium ≥ low limit normal without replacement therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ( include barrier method [ i.e. , condom ] ) 3 month completion study therapy No impaired cardiac function , include follow : QTc &gt; 450 msec screen ECG Congenital long QT syndrome History presence sustain ventricular tachycardia History ventricular fibrillation Torsades de pointes NYHA class IIIIV congestive heart failure Uncontrolled hypertension No severe gastrointestinal ( GI ) disorder , uncontrolled epilepsy , know glucose6phosphate dehydrogenase ( G6PD ) deficiency , know porphyria , moderate severe psoriasis , know myasthenia gravis , concurrent severe and/or uncontrolled medical condition No preexist maculopathy eye No significant history noncompliance medical regimen inability grant reliable informed consent PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior chemotherapy , investigational drug , major surgery recover More 6 month since change imatinib mesylate dose No concurrent anticancer therapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>